Kodak Deal On Hold Until Allegations Cleared
DFC Loan Of $765m Was Expected To Establish Pharmaceuticals Unit
Executive Summary
A major $765m loan agreed by the US International Development Finance Corporation to allow Kodak to establish a pharmaceuticals unit has been put on hold until allegations of wrongdoing are resolved, as rumors swirl about insider trading.
You may also be interested in...
Pharma Industry Reputation: What Is At Stake With COVID-19?
The massive need for a COVID-19 vaccine and treatments has heightened the biopharmaceutical industry’s visibility among consumers and the world’s largest biopharma companies are getting a boost in positive perception this year, according to a new FutureBrand survey. If sustained, this could have dividends in areas such as attracting industry talent and clinical trial participants. But much remains to be seen as biopharma navigates the final stretch of clinical development, regulatory review, distribution and patient access.
Deal Watch: RedHill Finds New Partner For Movantik
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Kodak Establishes Pharmaceutical Unit To Tackle Shortages
Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.